Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces two senior appointments to its clinical team. They will lead the Phase 3 program for Verona Pharma’s first-in-class product candidate,...
– Enrollment completed in third cohort of dose-escalation study at leading brain cancer hospitals in US; Investigators indicate interest in expanding study – Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced completion of enrollment...
Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced completion of patient recruitment in its pre-pivotal,...
LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine, today announced initiation of a Phase 2b study. On June 24th, 2019, the first subject was enrolled in ILiAD Biotechnologies IB-200P multicenter,...
— Compassionate use results to be presented at UMDF’s Mitochondrial Medicine 2019 symposium — — Minovia initiates U.S. operations in Cambridge, Mass. — — John Cox named Executive Chairman — Minovia Therapeutics today announced...
Gemcabene safely lowered serum triglycerides (TGs), the primary endpoint, in a subset of FPLD patients Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line results based upon the Company’s preliminary review of the limited top-line dataset from the...
Email
Text